The injectable cyclo-oxygenase-2 inhibitor parecoxib shows comparable efficacy to ketorolac

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1264, 2000-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics of Rofecoxib: A Specific Cyclo-Oxygenase-2 Inhibitor

By Davies N.M.

Clinical Pharmacokinetics, Vol. 42, Iss. 6, 2003-01 ,pp. : 545-556

Adis International

Access to resources Recommend Favorite

Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib: A Selective Cyclo-Oxygenase-2 Inhibitor

By Davies N.M.

Clinical Pharmacokinetics, Vol. 38, Iss. 3, 2000-03 ,pp. : 225-242

Adis International

Access to resources Recommend Favorite

Clinical Pharmacology of Lumiracoxib: A Selective Cyclo-Oxygenase-2 Inhibitor

By Rordorf Christiane M.

Clinical Pharmacokinetics, Vol. 44, Iss. 12, 2005-01 ,pp. : 1247-1266

Adis International

Access to resources Recommend Favorite

Celecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats

By Cuzzocrea S. Mazzon E. Serraino I. Dugo L. Centorrino T. Ciccolo A. Sautebin L. Caputi A.P.

European Journal of Pharmacology, Vol. 431, Iss. 1, 2001-11 ,pp. : 91-102

Elsevier

Access to resources Recommend Favorite

The cyclo-oxygenase-2 inhibitor, rofecoxib, attenuates mucosal damage due to colitis induced by trinitrobenzene sulphonic acid in rats

By Martin A.R. Villegas I. La Casa C. Alarcon de la Lastra C.

European Journal of Pharmacology, Vol. 481, Iss. 2, 2003-11 ,pp. : 281-291

Elsevier

Access to resources Recommend Favorite